Anti-ZC3HAV1 monoclonal antibody
Pre-made anti-ZC3HAV1 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to ZC3HAV1/ZC3HAV1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP2295-Ab-1/ GM-Tg-hg-IP2295-Ab-2 | Anti-Human ZC3HAV1 monoclonal antibody | Human |
GM-Tg-rg-IP2295-Ab-1/ GM-Tg-rg-IP2295-Ab-2 | Anti-Rat ZC3HAV1 monoclonal antibody | Rat |
GM-Tg-mg-IP2295-Ab-1/ GM-Tg-mg-IP2295-Ab-2 | Anti-Mouse ZC3HAV1 monoclonal antibody | Mouse |
GM-Tg-cynog-IP2295-Ab-1/ GM-Tg-cynog-IP2295-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ZC3HAV1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP2295-Ab-1/ GM-Tg-felg-IP2295-Ab-2 | Anti-Feline ZC3HAV1 monoclonal antibody | Feline |
GM-Tg-cang-IP2295-Ab-1/ GM-Tg-cang-IP2295-Ab-2 | Anti-Canine ZC3HAV1 monoclonal antibody | Canine |
GM-Tg-bovg-IP2295-Ab-1/ GM-Tg-bovg-IP2295-Ab-2 | Anti-Bovine ZC3HAV1 monoclonal antibody | Bovine |
GM-Tg-equg-IP2295-Ab-1/ GM-Tg-equg-IP2295-Ab-2 | Anti-Equine ZC3HAV1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP2295-Ab-1/ GM-Tg-hg-IP2295-Ab-2; GM-Tg-rg-IP2295-Ab-1/ GM-Tg-rg-IP2295-Ab-2; GM-Tg-mg-IP2295-Ab-1/ GM-Tg-mg-IP2295-Ab-2; GM-Tg-cynog-IP2295-Ab-1/ GM-Tg-cynog-IP2295-Ab-2; GM-Tg-felg-IP2295-Ab-1/ GM-Tg-felg-IP2295-Ab-2; GM-Tg-cang-IP2295-Ab-1/ GM-Tg-cang-IP2295-Ab-2; GM-Tg-bovg-IP2295-Ab-1/ GM-Tg-bovg-IP2295-Ab-2; GM-Tg-equg-IP2295-Ab-1/ GM-Tg-equg-IP2295-Ab-2 |
Products Name | Anti-ZC3HAV1 monoclonal antibody |
Format | mab |
Target Name | ZC3HAV1 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-ZC3HAV1 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP2295-Ag-1 | Recombinant multi-species ZCCHV/ ZC3HAV1/ ARTD13 protein |
Target information
Target ID | GM-IP2295 |
Target Name | ZC3HAV1 |
Gene ID | 56829,78781,252832,106997687,100856206,101101454,614589,100064774 |
Gene Symbol and Synonyms | 1200014N16Rik,2900058M19Rik,9130009D18Rik,9830115L13Rik,ARTD13,D6Bwg1452e,FLB6421,PARP13,ZAP,ZC3H2,ZC3HAV1,ZC3HDC2 |
Uniprot Accession | Q7Z2W4,Q8K3Y6 |
Uniprot Entry Name | ZCCHV_HUMAN,ZCCHV_RAT |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000105939 |
Target Classification | N/A |
The target: ZC3HAV1, gene name: ZC3HAV1, also named as ARTD13, FLB6421, PARP13, ZAP, ZC3H2, ZC3HDC2. This gene encodes a CCCH-type zinc finger protein. This antiviral protein inhibits viral replication by recruiting cellular RNA degradation machineries to degrade viral mRNAs. The encoded protein plays an important role in the innate immune response against multiple DNA and RNA viruses, including Ebola virus, HIV and SARS-CoV-2 (which causes COVID-19). [provided by RefSeq, Sep 2021].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.